(Q48876380)

16 February 2018

editorial

0 references

review article

1 reference

title

Antiangiogenesis: biology and utility in the treatment of gliomas. (English)

1 reference

16 February 2018

author name string

Marc C Chamberlain

series ordinal

1

1 reference

16 February 2018

publication date

1 October 2008

1 reference

16 February 2018

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

published in

1 reference

16 February 2018

volume

8

1 reference

16 February 2018

issue

10

1 reference

16 February 2018

page(s)

1419-1423

1 reference

16 February 2018

Antiangiogenic therapy in brain tumors

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

A new weapon for attacking tumor blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Vascular endothelial growth factor signaling pathways: therapeutic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Angiogenesis in gliomas: biology and molecular pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Mechanisms of angiogenesis in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Angiogenesis in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Genetic and hypoxic regulation of angiogenesis in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Pathophysiological consequences of VEGF-induced vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

VEGF as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Inhibition of angiogenesis and invasion in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Molecular mechanisms of glioma invasiveness: the role of proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Molecular pathways triggering glioma cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Expression of hypoxia-inducible factor 1? in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

VEGF inhibition and renal thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

Contribution of bone marrow–derived endothelial cells to human tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.10.1419

10.1586/14737175.8.10.1419

21 January 2018

Identifiers

DOI

1 reference

16 February 2018

PubMed ID

18928336

1 reference

16 February 2018